Navigation Links
Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
Date:3/2/2013

.

In her lawsuit, the woman is claiming that those problems were caused by blood clotting caused by her use of a NuvaRing IUD over seven years.

In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.

Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.

As with the NuvaRing lawsuits in the multidistrict litigation, the Philadelphia woman claims that the defendants were negligent in not fully informing the public and health care professionals about increased risk of blood-clotting from the use of the contraceptive, according to the court filing.

The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.

The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.

This flexibility was one of the marketing factors that made the NuvaRing what was described as an easy and healthy contraceptive choice to women who were not satisfied with the side effects caused by birth control pills and the necessity of taking them each day.

However, by 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Wright Hip Implant Lawyers at Bernstein Liebhard LLP Note Scheduling of Next Status Conference in Federal Wright Conserve Hip Replacement Litigation
2. Massachusetts' Deval Patrick Wins "Green Governor of the Year Award" -- First State to Win Federal Approval for Offshore Wind Farms says BE
3. Securityhunter Hires DigitalFury Technologies to Furnish Program Management Support for Federal Electronic Security System Programs
4. The ethics of access: Comparing 2 federal health care reform efforts
5. Federal Way Retirement Community to Host Event on Senior Living Options and Special Programs
6. Michigan Criminal Attorney, Loren Dickstein, Successfully Assists Client with Avoiding Serving Time in Federal Prison
7. North Shore-LIJ awarded $300,000 federal grant for prostate cancer research training
8. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
9. DePuy ASR Hip Recall: Status Conference Held in Federal DePuy ASR Hip Litigation in Ohio
10. DePuy Pinnacle Lawsuits: Explant Preservation Order Issued in Federal DePuy Pinnacle Hip Litigation
11. Actos Bladder Cancer Lawsuits: Next Status Conference in Federal Actos Litigation Scheduled for January 24, 2013, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... (HealthDay News) -- Leaving the car at home and getting ... for your health, a new study indicates. Researchers looked ... that 76 percent of men and 72 percent of women ... of women used public transit, and 14 percent of men ... who drove to work weighed more and had higher levels ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Parents and kids across the nation are ... means buying textbooks and arranging after school care, there ... part of the annual re-commitment to your child’s education; ... Association, 27% of students say they experience "extreme stress" ... are stressed by school pressures. The study, Stress in ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
... Resuscitating hopelessly ill patients too slowly to save their ... prolongs death and suffering, according to the November issue ... Jacinta Kelly, from Trinity College Dublin, has called for ... the practice of slow codes and highlighted the need ...
... Ellex Medical Lasers,Limited (ASX: ELX), a global leader ... ultrasound systems, announced today that the initial,results of ... be presented by Peter Hamilton MD, FRCOph at ... which takes place,November 10-13, in New Orleans. Dr. ...
... Amira Pharmaceuticals, a small,molecule pharmaceutical company focused on ... disease linked to the eicosanoid pathway,today announced the ... development. Dr. Raizon-Ounis brings 20 years of ... clinical research & licensing executive with,Roche Palo Alto. ...
... convenience for on-the-go snacking, COLUMBUS, Ohio, ... ),today announced the launch of new Fruitified(TM) ... four,great-tasting flavors: Apple Cinnamon, Blueberry, Banana Nut ... an excellent source of,protein and calcium and ...
... play role in autism, asthma,and other chronic health ... National Autism,Association (NAA) announced today a nationwide initiative ... program created by,the Deirdre Imus Environmental Center for ... to eliminate the serious,dangers posed to children from ...
... to the Third Quarter of 2006- ... During the Quarter-, PRINCETON, N.J., Nov. 1 Orchid ... identity DNA testing,services, today reported its financial results for the ... the third quarter of 2007,compared to $15.7 million for the ...
Cached Medicine News:Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 2Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 2Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 4Health News:Amira Pharmaceuticals Appoints First Vice President of Development 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 3Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 7
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... Medicine Knot Pusher is a reusable instrument used ... Knot Pusher is utilized in the handling and ... two piece shaft allows the surgeon to place ... pushing. The ring handle allows the surgeon ease ...
Medicine Products: